Navigation Links
Dr. Wayne Hachey Joins Protein Sciences' Leadership Team
Date:2/20/2013

MERIDEN, Conn., Feb. 20, 2013 /PRNewswire/ -- Protein Sciences Corporation announced today that Wayne Hachey , DO (Colonel, U.S. Army, ret.) has joined the Company's management as Head, Government and Clinical Affairs.  Dr. Hachey is a physician who has dedicated 28 years of service to the military healthcare system, including six years as a subject matter expert advising senior Department of Defense (DoD) leadership regarding the DoD's vaccine policy.  He was also responsible for developing the overarching DoD mitigation response to pandemic influenza and directed the implementation of that policy during the 2009 H1N1 pandemic.  Most recently, Dr. Hachey served as the Chief of Public Health for the 1st Medical Brigade in Afghanistan where he provided public health leadership to protect over 98,000 U.S. troops.  He is board certified in Public Health, Pediatrics and Neonatal-Perinatal Medicine and has won numerous awards, including the Defense Meritorious Service Medal, Meritorious Service Medal, NATO (Afghanistan) and Afghanistan Campaign Medal and Unit Combat Patch. 

Dr. Manon Cox , MBA, President and CEO of Protein Sciences commented, "We are delighted to welcome Dr. Hachey to our team."  She added, "In his new role, his primary responsibility will be to play a key role in our Company's interactions with government agencies."

Dr. Hachey will represent Protein Sciences at the following meetings this week where the Company's revolutionary new influenza vaccine Flublok® will be presented:

The Advisory Committee on Immunization Practices (ACIP) Meeting
February 20-21, 2013
CDC, Atlanta, GA

2013 AAAAI Annual Meeting
February 22-26, 2013
San Antonio, TX

About Us

Protein Sciences Corporation is a vaccine development and protein production company based in Meriden, CT that is dedicated to saving lives and improving health through the creation of innovative vaccines and biopharmaceu­ticals. Our proprietary baculovirus expression vector system (BEVS) technology provides a fast, reliable and inexpensive platform for the production of high quality recombinant proteins, making it a powerful tool for producing vaccines and therapeutics when they are needed most.  BEVS technology is covered by broad patents that include our proprietary expresSF+® cell line that we use to make all of our products.

On January 16, the FDA approved Flublok, a novel influenza vaccine for the prevention of influenza in adults aged 18-49 years old. The FDA has called Flublok a revolutionary vaccine as no eggs or live influenza virus is used in its manufacturing process. In addition, the product does not contain a preservative (e.g., thimerosal), latex, adjuvants or other additives. 

Learn more at www.proteinsciences.com and www.flublok.com.


'/>"/>
SOURCE Protein Sciences Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Immune Design Corp. Appoints Wayne R. Gombotz, Ph.D. as Chief Development Officer
2. Michael Cusumano, MITs Sloan Distinguished Professor of Management, Joins Quantum Leap Innovations Board of Directors
3. Robert Farrell Joins Bionovos Board of Directors
4. Former Sanofi-aventis and US Oncology Executive Joins New Century Health as Chief Executive Officer
5. Scott Brooks Joins Regenesis Biomedical as Chief Operating Officer
6. First Choice Rehabilitation Specialists Joins Select Medical
7. Excel Life Sciences Joins DATATRAKs Connect Partner Program
8. Marina Biotech, Inc. Joins OTCQX
9. Richard H. Scheuermann, Ph.D. Joins J. Craig Venter Institute as Director of Informatics
10. Dr. David L. Blecker MD, MPH, F.A.C.P. Joins Inergetics Advisory Board to Co-Develop and Market Products to Penetrate Nephrology Market
11. QIAGEN Joins Grand Challenges in Global Health Initiative to Bring Advanced Point-of-Care Diagnostics to Worlds Poorest Countries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... 2017 , ... A new study published in Fertility and ... in vitro fertilization (IVF) transfer cycles. The multi-center matched cohort study ... comparing the results from the fresh and frozen transfer cohorts, the authors of ...
(Date:10/10/2017)... CA (PRWEB) , ... October ... ... a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today ... of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration ...
(Date:10/10/2017)... International research firm Parks Associates announced today that ... TMA 2017 Annual Meeting , October 11 in Scottsdale, ... security market and how smart safety and security products impact the competitive ... Parks Associates: Smart Home Devices: Main ... "The residential security market has experienced continued ...
(Date:10/10/2017)... ... 2017 , ... The Pittcon Program Committee is pleased to ... who have made outstanding contributions to analytical chemistry and applied spectroscopy. Each award ... conference and exposition for laboratory science, which will be held February 26-March 1, ...
Breaking Biology Technology:
(Date:6/23/2017)... ITHACA, N.Y. , June 23, 2017 /PRNewswire/ ... leader in dairy research, today announced a new collaboration ... reduce the chances that the global milk supply is ... dairy project, Cornell University has become the newest academic ... Supply Chain, a food safety initiative that includes IBM ...
(Date:5/16/2017)... 16, 2017   Bridge Patient Portal , ... MD EMR Systems , an electronic medical ... GE, have established a partnership to build an ... the GE Centricity™ products, including Centricity Practice Solution ... These new integrations will allow healthcare delivery ...
(Date:4/18/2017)... a global expert in SoC-based imaging and computing solutions, has developed ... the company,s hybrid codec technology. A demonstration utilizing TeraFaces ® , ... showcased during the upcoming Medtec Japan at Tokyo Big Sight April ... Vegas Convention Center April 24-27. ... Click here for an image of the M820 ...
Breaking Biology News(10 mins):